In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions-Reference-Cited by-同舟云学术

In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

Published:2013-11-20 Issue:7 Volume:34 Page:e217-e228
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Mangia Alessandra¹,Bányai Tivadar²,De Bartolomeo Giuseppe³,Gervain Judit⁴,Habersetzer François⁵,Mulkay Jean-Pierre⁶,Ouzan Denis⁷,Parruti Giustino⁸,Passariello Nicola⁹,Remy Andre-Jean¹⁰,Rizzetto Mario¹¹,Shiffman Mitchell L.¹²,Tice Alan D.¹³,Schmitz Manuela¹⁴,Tatsch Fernando¹⁵,Rodriguez-Torres Maribel¹⁶

Affiliation:

1. Liver Unit; IRCCS Hospital ‘Casa Sollievo della Sofferenza’; San Giovanni Rotondo Italy

2. Department of Infectology; Pándy Kálmán Hospital; Gyula Hungary

3. Internal Medicine Liver Unit Hospital; F. Veneziale; Isernia Italy

4. Department of Internal Medicine/Hepatology and Molecular Diagnostic laboratories; Szent Gyorgy Hospital; Székesfehérvár Hungary

5. Pôle Hépato-digestif, Inserm 1110; Université de Strasbourg; Nouvel Hôpital Civil; Strasbourg France

6. Hepato-gastroenterology; CHU Saint-Pierre; Brussels Belgium

7. Institut Arnault Tzanck; Saint-Laurent-du-Var France

8. Infectious Disease Unit; Santo Spirito General Hospital; Pescara Italy

9. Department of Geriatrics and Metabolic Diseases; University of Naples; Naples Italy

10. Centre Hospitalier de Perpignan; Perpignan France

11. University of Turin; Turin Italy

12. Liver Institute of Virginia; Bon Secours Health System; Richmond and Newport News VA USA

13. Infections Limited Hawaii; Honolulu HI USA

14. IST GmbH; Mannheim Germany

15. F. Hoffmann-La Roche Ltd; Basel Switzerland

16. Fundación de Investigación; San Juan PR USA

Funder

F. Hoffman-La Roche Ltd

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12352/fullpdf

Reference41 articles.

1. EASL clinical practice guidelines: management of hepatitis C virus infection;European Association for the Study of the Liver;J Hepatol,2011

2. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chroninc hepatitis C virus infection;Fried;J Hepatol,2011

3. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials;Marcellin;Hepatology,2012

4. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

5. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study;PLOS ONE;2015-07-31